MedPath

A study to develop, open source, comprehensive database of molecular profiles (a form of testing that classifies tumors based on this genetic make-up) of cancer prevalent in Indian populations.

Not Applicable
Conditions
Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Registration Number
CTRI/2023/09/058135
Lead Sponsor
IGBI
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients of Indian origin/ethnicity

2.Patients with histopathological proven invasive breast cancer of any pathological subtype. 3.Female patients who are older than 18 years of age.

4.Patients who are willing to provide written informed consent for participating in the study.

5.Patients with tumor of any estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status by immunochemistry (IHC). Patients who have HER2 IHC 2+ tumor will be included, if in situ hybridisation (ISH) for HER2 amplification has or can be been performed.

6.Patients with bilateral cancer. Such cases would be considered as two separate tumors (if both samples are available).

7.Patients with contralateral cancer (Sample would be considered as new tumor).

8.Patients who have newly diagnosed treatment naïve breast cancer (tumor biopsy from primary or metastatic tumor) OR who have received neoadjuvant/adjuvant chemotherapy and/or endocrine therapy (sample from primary tumor).

Exclusion Criteria

1.Patients who are not of Indian origin/ethnicity

2.Patients, who are unwilling to provide informed consent for participating in the study.

3.Patients who, in the opinion of the investigator, are not reliable for follow up.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath